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In this thesis, the method development and investigation of different liposomal formulations 
to incorporate and retain Camptothecin (CPT) is described. CPT is a potent anticancer drug 
that has shown to be active against a broad spectrum of cancers. However, due to its 
challenging physicochemical properties, like poor water solubility, severe toxic effects to 
normal tissues and instability, its clinical development has been limited for nearly 40 years. A 
strategy to overcome CPT’s challenging properties is to use liposome-based carrier system. 
By taking advantage of this carrier system, we may solubilise CPT in the phospholipid bilayer 
of liposomes, protect it from blood proteins and achieve a selective drug accumulation in 
tumor tissues or tumor-associated cells by enhanced permeability and retention effect (EPR).     
A good liposome formulation of clinical utility must fulfil two important criteria. The 
liposomal drug carrier must incorporate CPT in the liposomal bilayer in a relevant therapeutic 
concentration and be able to retain the drug within the liposome to make it bioavailable at the 
target site after i.v. administration. The focus of this thesis was to study different liposomal 
formulations and their ability to incorporate and retain CPT. Screening of eight different 
liposome formulations with respect to association with CPT was performed. The 1,2-di-oleyl-
3 trimethyl-ammonium-propane (DOTAP) containing formulations showed superior 
incorporation capacity, giving an CPT incorporation of 250 µg/130 µmoles lipid. The 
DOTAP containing formulations exhibited as well a trend toward higher retention ability in 
serum compared to the other formulations. Although they showed better retention ability, only 
25 % of the drug was associated with the liposomes, which is far from being optimal. One of 
the important criteria mentioned above for liposomes as drug delivery systems is their ability 
to remain stable in blood circulation for prolonged time in order to reach the specific target 
and to avoid rapid clearance by RES after i.v. injection. To achieve this, PEG decoration on 
the liposome surface can be employed. We chose to PEGylate DOTAP formulations in order 
to get a better understanding of this system. PEGylation lead, as expected, to increased 
stability of the liposomes, however a reduced incorporation capacity was observed. The 
presence of 1 % and 10 % PEG gave better retention and slower leakage from the liposomes. 
We conclude that DOTAP inclusion in our liposomes increased the incorporation of CPT into 
the lipid bilayer, that liposomal retention in our current formulations must be improved, and 
while PEGylation is necessary in order to prevent rapid in vivo clearance, the inclusion of 
PEG reduces incorporation, and therefore further studies are needed in order to improve 
































AcCN                     Acetonitrile 
Chol                        Cholesterol  
CPT                        Camptothecin  
CPT-11                   Irinotecan 
DMSO                    Dimethyl sulphoxide 
DOPG                     Dioleoylphosphatidylglycerol 
DOTAP                   1,2-di-oleyl-3 trimethyl-ammonium-propane 
DPH                        1,6-Diphenyl-1,3,5-hexatriene  
EPC                         Egg phosphatidylcholine 
EPR                         Enhanced permeability and retention  
HPLC                      High performance liquid chromatography 
HSA                         Human serum albumin 
i.v.                            Intra venous  
LC                            Liquid chromatography  
LUV                         Large unilamellar vesicle 
MLV                        Multilamellar vesicle 
PA                            Phosphatidic acid 
PB                            Phosphate buffer  
PBS                          Phosphate buffered saline  
PC                            Phosphatidylcholine  
PCS                          Photon correlation spectroscopy  
PE                             Phosphatidylethanolamine 
PEG                          Poly(ethylene glycol) 
PG                            Phosphatidylglycerol 
PI                              Phosphatidylinositol 
PL                             Phospholipid 
PS                             Phosphatidylserine 
RES                          Reticuloendothelial system 
SD                            Standard deviation  
SUV                         Small unilamellar vesicle 
Topo-I                      Topoisomerase I 
UV                           Ultraviolet  




Over the past thirty years, liposomes are becoming important as a delivery system for 
therapeutic agents, chemotherapeutics, antigens, immunomodulators, imaging and genetic 
materials. A large number of liposome based drugs are in preclinical and clinical research. 
Cosmetic industry has also shown great interest in liposomes, and today there are many 
liposome-based cosmetic formulations e.g. skin-care products available on the market 
(Garidel et al., 2000). 
 
1.1 Camptothecin 
Camptothecin (CPT) is a potent anticancer agent that has shown significant cytotoxic activity 
(Watanabe et al., 2008). CPT is an alkaloid derived from the bark of the Chinese tree 
Camptotheca acuminate, and was isolated already in 1966 by the group of  Wall and Wani  
(Wall et al., 1966). But due to its limitations, like poor water solubility and the undesired 
physical and chemical properties described below, their pharmaceutical development and 
clinical implementation has been impaired and research on other chemotherapeutic agents 
prioritized. In the 1980s the molecular target for CPT was however identified, again raising 
researchers’ interest in and attention to CPT as an anticancer agent (Hsiang and Liu, 1988) 
(Mattern et al., 1987). 
CPT’s anticancer effect lays in its ability to bind to DNA and inhibit Topoisomerase I (Topo-
I) at physiological pH as shown in Figure 1.1. Topo-I is a central enzyme in the process of 
DNA replication. It is responsible for winding and unwinding of the supercoiled DNA 
composing the chromosomes. Transcription of DNA cannot occur, if the chromosomes are 
not unwound. Further protein synthesis is inhibited, inducing apoptosis (Venditto and 
Simanek, 2010). The primary mechanism of CPT is S-phase specific, which means that it is 








Figure 1.1: CPT is binding to Topo-I and arrests the replication fork leading to cell death 
(reprinted with permission from Dr. Holsæter (Saetern, 2004)) 
 
It is known that CPT exists in a pH dependent equilibrium between a lactone form and a 
carboxylate form (Figure 1.2). CPT is present in its active lipophilic lactone form at pH    
below 6. At physiological pH, CPT is largely present as its significantly less biologically 
active and more water soluble carboxylate form. Under physiological conditions and in 
human plasma CPT-lactone is rapidly hydrolysed to the open carboxylate form. The 
carboxylate form of CPT binds with a 100-150 fold higher affinity to human serum albumin 
(HSA) compared to the lactone form, which drives the equilibrium toward the open-ring 
carboxylate form (Figure 1.3). HSA-CPT binding makes the inactive carboxylate form 
inaccessible for cellular uptake. Moreover, the inactive carboxylate form is excreted by the 
kidneys, and causes several toxicity problems like haemorrhagic cystitis and myelotoxicity. 
Red blood cells/cell membranes on the other hand stabilize the lactone form, also shown in 
Figure 1.3 (Mi and Burke, 1994) (Saetern et al., 2004a). The biologically active form of CPT 
has a very short half-life (approximately 12 min), and in presence of human plasma 99% of 
the drug is converted to its less active and potentially toxic carboxylate form (Burke, 1996). 










Figure 1.2: Equilibrium between the carboxylate and lactone form of CPT (reprinted with 
permission from Dr. Holsæter (Saetern, 2004)). 
 
Currently, there are only two CPT-analogues that have passed the clinical trials. Irinotecan 
(Campto®) and topotecan (Hycamptin®) are the two derivatives and have been approved for 
treatment of the ovarian carcinoma, small-cell lung cancer and colorectal cancers. These two 
CPT derivatives are both water soluble, due to molecular modifications, and also exhibit a 
reduced binding affinity for HSA (Li et al., 2006). However, there are still problems with 
these derivatives’ unstable E-ring, which is converted to the carboxylate form at physiological 
pH (Emerson, 2000). Researchers are still interested in finding new and better ways to solve 
CPTs’ stability problems, and this may be achieved by incorporating this drug in liposomal 
drug carrier, thereby overcome some of CPT’s challenges and keeping it in its active lactone 
form (Watanabe et al., 2008). This can be achieved by the fact that lipids can dissolve the 
lipophilic drug and the pH can be controlled inside the liposome in such a way that the 
equilibrium is forced toward the active lactone form (see Figure 1.3). The lactone form has 
also shown to be stable when harboured in the liposome bilayer (Burke et al., 1992). The drug 
is in addition protected from HSA and the complexing with the carboxylate form is avoided 
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Figure 1.3: Schematic description of lactone and carboxylate equilibrium in both liposome 
membrane and in blood circulation 
 
1.2 Liposomes 
1.2.1 Definition and background 
Liposomes are self-assembling spherical vesicles with a size ranging from 20 nm to 10 µm. 
Liposomes may exist as uni- and multilamellar vesicles. Unilamellar vesicles consist of a lipid 
bilayer separating the aqueous core from an outer aqueous environment, while multilamellar 
vesicles have multiple lipid bilayers separating the different aqueous environments (Brandl, 
2001). Liposomes normally consist of different types of naturally occurring phospholipids, 
but other lipids such as cholesterol can be included to tune the liposome properties. In order to 
obtain liposomes of mixed composition, the lipids are dissolved in an organic solvent, which 
is subsequently evaporated from the lipid mixture and a dried lipid film is obtained. 
Liposomes are formed spontaneously when dry lipids is dispersed in an aqueous media. They 
have the ability to function as drug carriers for both hydrophilic, lipophilic and amphiphilic 
drugs. Hydrophilic drugs can be encapsulated in to the aqueous core, while lipophilic and 
amphiphilic drugs can be incorporated within the lipophilic bilayer (see Figure 1.4) (Chrai et 






Figure 1.4: Liposomes with lipophilic drugs incorporated in the phospholipid bilayer 
(reprinted with permission from Dr. Holsæter (Saetern, 2004))  
 
By using liposomes as drug-delivery carriers, we may keep CPT in its active lactone form by 
protecting CPT from degradation and HSA binding in the blood stream (Emerson, 2000). And 
because liposomes themselves are formed from naturally occurring lipids of low intrinsic 
toxicity, they are non-immunogenic and biodegradable in the body (Chrai et al., 2002). 
 
1.2.2 Lipids in liposome products 
1.2.2.1 Phospholipid (PL) 
Phospholipids (PLs) typically found in high proportions in cell membranes of living matter, 
are an important component in liposome formulations. PL consists of two fatty acids linked to 
a polar head group, and they have either glycerol (Figure 1.5) or sphingomyeline as the back 
bone. PLs are amphipathic molecules, and have both hydrophobic and hydrophilic groups. 
The two hydrocarbon chains constitute the hydrophobic tails, while the phosphate group and 
its polar attachment constitute the hydrophilic group (Cooper and Hausman, 2009).  
PLs can consist of different head and tail groups that affect the surface charge and bilayer 
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Figure 1.5: Structural formula of glycerophospholipid (reprinted with permission from 
(Flaten, 2003)) 
 
Phosphatidylcholine (PC) is the most commonly phospholipids employed in liposomes, and 
can be obtained from both natural and synthetic sources. PC is zwitterionic and consists of a 
hydrophilic headgroup with a quaternary ammonium moiety choline, which is linked to a 
glycerol via a phosphoric ester (Brandl, 2001). 
The stability of the liposome membrane depends on the packing of the hydrocarbon chains of 
the lipid molecules. The hydrocarbon chain length and degree of saturation of the acyl chains 
influences at which temperature, the main transition temperature (Tm), the membrane 
transforms from a fully extended and closely packed “gel phase” to a liquid crystalline 
disordered “fluid phase”. In general, fluid membranes are more permeable to solutes than 










Table 1.1: The most common glycerophospholipids 
The esterified 
group 
Name of the phospholipid Abbreviation Net charge at    
pH 7 
-H Phosphatidicacid PA Negative 
-CH2CH2N+(CH3)3 
 
Phosphatidylcholine PC Zwitterionic 
-CH2CH2NH3+ Phosphatidylethanolamine PE Zwitterionic 
-CH2CHOHCH2OH Phosphatidylglycerol PG Negative 
-HC6H5(OH)5 Phosphatidylinositol PI Negative 
-CH2CHNH3+COO- Phosphatidylserine PS Negative 
 
The charge of the lipid used in liposome formation dictate the surface charge of the 
liposomes. The surface charge of liposomes can be tailored by replacing phosphatidylcholine 
(PC) partly with negatively or positively charged (phospho)lipids (Table 1.1), which induces 
electrostatic repulsion and stabilization against liposome fusion (Ogihara et al., 2010). The 
surface characteristics of liposomes may also be altered by modifying lipids with hydrophilic 
moieties e.g. polyethylene glycol (PEG) to membrane bilayers which is described more below 
(Brandl, 2001). 
 
1.2.2.2 Cholesterol (Chol) and other employed lipids 
Cholesterol (Chol) is one of the commonly used lipids in liposome formulations, and its 
incorporation into the lipid bilayer has a major effect on the liposome properties. The 
presence of Chol in the lipid bilayer enhances the stability and form highly ordered and rigid 
membrane with fluid like characteristics (Lee et al., 2005). 
Chol molecular structure (Figure 1.6) with the four hydrocarbon rings makes it strongly 
hydrophobic. The presence of the hydroxyl group (OH) attached to the end of Chol makes 
that part weakly hydrophilic (Cooper and Hausman, 2009). Chol can be incorporated into the 
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lipid bilayers at concentrations up to 1:1 molar ratio, and does not form a bilayer on its own. 
Therefore other phospholipids are needed to form a bilayer. Due to its amphiphatic properties, 
Chol inserts itself in the bilayer with its OH-group oriented towards the aqueous core, and the 
rigid hydrophobic tail toward the phospholipid bilayers (Perrie and Rades, 2010). 
 
 
Figure 1.6: General structure of cholesterol (Chol) (www.avantilipids.com) 
            
1,2-di-oleyl-3-trimethyl-ammonium-propane (DOTAP) is another example of lipids used in 
liposome formation. DOTAP is a cationic lipid with two unsaturated fatty acids. It consists of 
propane as backbone and trimethylammonium as the hydrophilic head group as shown in 
(Figure 1.7). 
 







1.2.3 Characterization of liposomes 
Classifications of liposomes are based on their size and lamellarity. Different size and 
lamillarity depends on their composition and their method of preparation. 
Liposomes are usually categorized in to three main types, based on the size and lamellarity, as 
follows. 
• Multilamellar vesicles (MLVs) is one of the three categorizes. These are vesicles with 
a size ranging from 100 nm to several micrometers, depending on the method of 
preparation. They consist of a large number concentric lamellar, and due to their large 
lamellarity they are more suited to incorporation of lipophilic molecules compared to 
hydrophilic substances 
• Small unilamellar vesicles (SUVs) are vesicles consisting of single bilayer and can 
theoretically be as small as about 20 nm. They are more suitable for parenteral 
administration than MLVs, because of their homogeneity in size. Their small size 
results in lower amount of encapsulation of hydrophilic drugs.  
• Large unilamellar vesicles (LUVs) are vesicles generally with size in the order of     
100 nm, consisting of one single lamellar. They can entrap a higher amount of 
hydrophilic drugs due to their larger aqueous core compared with SUVs (Perrie and 
Rades, 2010). 
 
1.2.3.1 The role of liposome size 
The rate of the opsonisation and clearance by the reticuloendothelial system (RES) of the 
injected liposomes from the blood circulation is dependent on the composition and size (Liu 
et al., 1995). RES is part of the immune system and their main function is to eliminate foreign 
materials from the body (Harashima et al., 1994) (Perrie and Rades, 2010). RES consists of 
cells such as blood monocytes and macrophages found mainly in the Kupffer cells in liver, the 
lung and the spleen. Shortly after i.v injection, the liposomes become coated by serum 
proteins called opsonins. Once they are opsonised, they will rapidly be phagocyted by the 
RES cells, and the major part of the injected liposomes will be accumulated in the liver and 
spleen (Maurer et al., 2001). 
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Large liposomes (>200 nm in diameter) are rapidly opsonised and taken up by the (RES) 
disappear from the blood circulation within short time and primarily end up in the spleen. 
Opsonisation decreases with a decreasing in liposome size. Small liposomes have a relatively 
larger surface area, and will have a lower density of opsonins on the membrane surface which 
results in lower uptake by the macrophages (Liu et al., 1995). Liposomes with a size of 70 to 
200 nm will have a greater chance to escape from RES and remain in the circulation longer 
and then reach the target. Due to extravasations through the fenestrated capillary walls in the 
liver, the small liposomes (< 70 nm in diameter) show shorter circulation time. The structure 
and architecture of the blood capillary walls varies in different organs and tissues. There are 
structure differences between healthy and tumour capillaries and blood supply to the organs 
and tissues is somewhat different (Brandl, 2001). 
 
1.2.3.2 The role of the surface charge and membrane characteristics 
Lipid organization in the liposome membranes has a major role on the physical membrane 
properties such as permeability, membrane elasticity, surface charge and binding properties of 
proteins, and is of equal importance for clearance as compared to liposome size (Garidel et 
al., 2000). 
Neutral-charged liposomes with tightly packed membranes tend to remain longer in the 
circulation and exhibit increased drug retention, compared to charged systems. Protein 
opsonisations onto the liposome surface are reduced due to the tightly packed and rigid 
membrane. The presence of Chol in liposome formulations may change the packing of the 
phospholipids to a more ordered and rigid membrane and may stabilize to avoid drug leakage. 
Moreover, this may reduce binding of opsonins on the liposomes and may improve stability 
and retention of liposomes in vivo (Maurer et al., 2001).   
Certain plasma proteins have an affinity for liposomes, and the affinity is enhanced if the 
liposome is charged.  In particular cationic systems are expected quickly interaction with 
various components in systemic circulation and thus having shorter half life in vivo (Maeda, 
2001). It is also known that anionic liposomes containing negatively charged lipids such as 
phospatidylserine (PS), phosphatidicacid (PA) and phosphatidylglycerol (PG) are quickly 
taken up by macrophages and thus disappear from the circulation in short time (Liu et al., 
1995) (Massing and Fuxius, 2000).  
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1.3 Long circulating liposomes 
Liposomes for use as drug delivery systems must be stable in the blood circulation for 
prolonged time to reach the specific target other than RES. In order to avoid rapid clearance 
by the RES after i.v. injection and thus allowing them to remain in the circulation for 
prolonged periods, PEG attachment on the liposome surface can be used. PEG is a 
hydrophilic polymer with varying in molecular weight due to the number on monomer repeat 
units. The polymer acts as a steric barrier with the flexible chains forming “brushes” which 
extending out from the surface (se Figure 1.8), thereby preventing interaction of opsonins and 
uptake by phagocytic cells. These liposomes are known as “stealth liposomes”, and have good 
solubility properties in aqueous media (Torchilin and Papisov, 1994) (Allen, 1994). Although 
PEG is non-biodegradable, it does not form any metabolites, has a very low toxicity profile 
and does not accumulate in the RES (Perrie and Rades, 2010).   
 






1.3.1 Liposomes in cancer therapy 
Liposomes are used for drug delivery in cancer therapy due to their unique properties.  They 
have the distinct advantages of being non-toxic and degradable in the body because of their 
naturally occurring lipids as main content. Liposomes have also a unique ability to entrap both  
hydrophilic and lipophilic drugs to its compartment and lead to a controlled release effect 
(Massing and Fuxius, 2000). Drug entrapment in the liposomes has also shown reduced drug 
toxicity due to minimized uptake in other tissues such as heart, kidneys and gut. Beside their 
ability to protect the entrapped drugs from degradation in the blood stream, their most 
important properties is the ability to accumulate in the tumors by passive targeting due to the 
enhanced permeability and retention effect (EPR) (Figure 1.9). The EPR effect is due to the 
differences between the vasculature in tumors and healthy tissues. Because of the 
angiogenesis, the blood vessels in tumor are more leaky and have less perfect cellular packing 
leading to bigger gaps between the cells. Furthermore, the lymphatic system which is 
responsible for removing substances such as liposomes or other nanoparticles from the tissues 
is marginally expressed compared to normal tissue (Jain, 1987). By utilizing the EPR effect, 
small liposomes (< 70 nm) are able to escape vasculature within tumors and accumulate there 
via passive targeting effect (Brandl, 2001). 
 
 
Figure 1.9: Accumulation of liposomes in tumour tissues due to EPR effect (reprinted with 




A range of water soluble, low-molecular weight anticancer drug compounds such as e.g. 
doxorubicin, have as said above been demonstrated to show significantly enhanced 
accumulation within solid tumors upon entrapment in liposomes when administered i.v. due 
to the EPR effect. Unfortunately such tumor-targeting by liposomal carriers so far could not 
be achieved to the same extent for other cytostatics, especially for the class of poorly water 
soluble compounds. We hypothesize that a premature loss of the anticancer compound from 
the liposome carrier is the reason for this (Fahr et al., 2006). A central prerequisite for 
successful delivery of the anticancer drug, namely that the drug remains associated with the 
liposome carrier during transit in the blood stream and is only released upon arrival at the 
target site, may not have been sufficiently fulfilled with the so far investigated liposome 
formulations of such drugs.  
The first and the most important aim of this thesis was to investigate CPT incorporation as 
well as the retention ability of different liposome formulations in order to identify which 
factors are crucial for obtaining the optimal liposome formulation for in vivo CPT delivery. 
The second aim was to come up with a formulation exhibiting surface characteristics that 
makes the liposomes likely to circulate over longer time periods in the blood. In order to 
perform these studies, appropriate methods were needed, thus a third aim was to establish 













2 MATERIALS & METHODS 
2.1 Materials 
Table 2.1: Chemicals 
Chemicals Purity Quality Producent 
Acetic acid 100 % Glacial, p.a.* Merck, Germany 
Acetone Min. 99.5 % p.a.* Merck, Germany 












4 % ACL Agarose 
Beads  





Min. 99.0 % Extra pure Merck, Germany 
DMSO 99.5 % GC Sigma-Aldrich chemie 
GmbH,Germany 
Ethanol 96 % For analysis Sigma-Aldrich chemie, 
GmbH, Germany 











Min. 99.5 % p.a. Merck, Germany 
Sodium Chloride Min. 99.8 % p.a. Sigma-Aldrich chemie 
GmbH, Germany 
Triton X-100 97 %  Sigma-Aldrich Chemie 
GmbH, Germany  
Triethylamin Min. 99 % For synthesis Merck, Germany 
p.a.= pro analysis 
 
Table 2.2: Lipids 
Name Abbreviation Charge  Producer 
1,2-dioleoyl-sn-glycero-3-
phosphatidylglycerol 




DOTAP + Avanti Polar, USA 
Cholesterol  CH No charge Sigma-Aldrich 
GmbH, Germany 












Table 2.3: Equipment 
Equipment Type Producer 
Bath sonicator  Branson®1510 Branson ultrasonics, USA 
Bath sonicator  Model G112SPIT Laboratory supplies Co., 
Inc., USA 
Centrifuge tubes  Polycarbonat tubes, thick-wall Beckman Instrument, USA 





Bio-Rad Laboratories, USA 
Dialyse cassette Slide_A-Lyzer Dialysis cassette  
10.000 MWCO 
0.5-3.0 ml capacity 
Thermo scientific, USA 
Eppendorf-tube Safe-Lock tubes 2.0 ml Eppendorf AG, GmbH, 
Germany 
Rotary evaporator Büshi R-124  rotary evaporator with 
vacuum pump v-500-system 
Büshi, Switzerland 
HPLC Waters 2690 Separation module 
Waters 474 Scanning Fluorescence 
detector  
Waters 2487 Dual λ Absorbance 
detector 
Symmetry C18-columm (3,9x150 
mm) 
Waters,USA 
Filter 0.22 µm non-sterile  syringe filters Pall Life Sciences, USA 
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Leica CTR 6000 microsystem Leica, Germany, GmbH 
Fluorescence 
spectrophotometer 
Perklin Elmer LS 55 Fluorescence 
spectrometer  
Perklin Elmer, UK 
Microtitre plates Costar® UV 96-well plate with UV 
transparent flat bottom, Acrylic 
Costar®, USA 
Microtitre plate reader Spectra Max 190 Microplate 
Spectrophotometer 
Molecular devices, USA 
PCS Submicron Particle Sizer, model 
370 
Nicomp,USA 
pH meter  744 pH meter Metrohm Metrohm Ltd, Switzerland 
Probe-Sonicator Ultrasonics Vibra Cell  VC 754    
750 Watt ultrasonic processor   
CVR 234 converter 
Needle probe 19 mm 
Sonics and Materials, USA 
Probe-Sonikator Sonics high intensity ultrasonic 
processor 500 Watt model  
Needle probe 13 mm 
Sonics and Materials, USA 
Ultracentrifuge Optima LE-80 Beckman,USA 
Vortex MS2 Minishaker IKA  Chiron AS 
Zetasizer  Nano series Malvern instruments, UK 







Isotonic phosphate buffered salines (PBS) 0.025 M  
1. 0.025 M di-sodiumhydrogenphasphate-dihydrat 
I.          di-sodiumhydrogenphosphate-dihydrat             8.90 g 
II.          Sodium chloride                                               15.16 g 
            III.        Distilled water                                                  ad 2000.0 ml 
   I and II are dissolved in III 
 
       2.   0.025 M Potassium dihydrogen phosphate 
I.           Potassium dihydrogen phosphate                     6.804 g 
II.          Sodium chloride                                                15.0 g 
III.        Distilled water                                                   ad 2000.0 ml 
 
I and II are dissolved in III  
Solution 1 and 2 are filtered through a 0.22 µm filter (cellulose acetate filters, Sartorius AG,                 










Phosphate buffer (PB) 0.025 M pH 3.0  
 I.    Ortho-Phosphoric acid 85 %                                  1.038 g 
 II.    Sodium hydroxide                                                 ad pH 3.0 
 III.   Distilled water                                                       ad 1000.0 ml  
 
I is dissolved in 250 ml III, II are added to the solution. Rest of III is added up to 1000.0 ml. 
The solution is filtered through a 0.22 µm filter (cellulose acetate filter, Sartorius AG, 
Germany). 
Triton- solution 10 % (w/w)  
              I.    Triton X-100                                                            10.0 g 
              II.   PB 0.025 M pH 3.0                                                  90.0 g (ad 100 g) 
 
I is dissolved in II. 
Mobile phase for HPLC analysis 
TEAA buffer 1 v/v %  
I.        Triethylamine                  20 ml 
II.       Distilled water                ad 2000.0 ml 
III.      Acetic acid                      ad pH 5.5 
 
I and 1500 ml II are mixed by a magnetic stirrer. III is added to obtain pH 5.5. Then the 
volumetric bottle is filled to 2000.0 ml with II. The pH value is controlled to be 5.5 using a   
pH-meter. The solution is filtered through a 0.22 µm filter (cellulose acetate filter, Sartorius 




2.3 Liposome preparation 
Liposomes can be prepared by several techniques (Torchilin and Weissig, 2003). We 
employed both film hydration and freeze drying method, in order to determine if there are any 
differences in the incorporation of CPT in liposomes. The most appropriate method was then 
used further.  
 
2.3.1 Lipid-CPT film preparation 
Lipid-CPT films were prepared by mixing the lipid solutions in the desired composition with 
solution of the active drug CPT in a round bottom flask. Stock solutions of 100 mg/ml were 
made with different lipids in chloroform or a chloroform:methanol mixture. Stock solutions of 
CPT in a mixture of chloroform:methanol (4:1 volume ratio) with a concentration of 2 mg/ml 
were also prepared.  After mixing the desired components, containing totally 1 mg CPT/130 
µmoles lipid, the solvents were removed on a Büshi R-124 rotary evaporator with vacuum 
pump 500-system (Büshi, Switzerland) for 45 minutes at 200 mPa on a water bath at 45 ˚C. 
After 45 minutes, the round bottom flask was removed from the water bath and the pressure 
was adjusted to 50 mPa for about 3 hours to remove traces of solvent and obtain a dry film. 
The lipid compositions of the different formulations which were prepared are given in Table 
2.4. 
 
Table 2.4: The lipid compositions (mol %) of the different formulations  
Lipids Formulations 
 1 2 3 4 5 6 7 8 
Chol   10      
E PC 100 90 90 85 80 85 85 85 
DOPG  10       
DOTAP    15 20 15 15 15 
PEG      1 5 10 
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2.3.2 Lipid-CPT freeze-drying preparation 
The freeze-dried samples were prepared by mixing solutions of the desired lipid EPC and the 
active ingredient CPT in injection vials. 1 ml of lipid-CPT solution containing 100 mg lipid 
and 1 mg CPT stock solution was used for freeze-drying. The vials with the mixture were 
shock-frozen in liquid nitrogen for 1 minute and placed in a freeze dryer (beta 2-16 equipped 
with an LMC-2 controller, Martin Christ Gefriertrocknungsanlagen GmbH, Osterode am 
Herz, Germany) with opened stoppers. The freeze-drying method are described earlier 
(Saetern et al., 2004b) and was performed for 65 hours at temperatures from - 40 °C to 45 °C 
with pressure declining from 800 mbar to 0.008 mbar. After freeze-drying the PL-CPT vials 
were sealed with aluminium closures and stored at – 80 °C. 
 
2.3.3 Rehydration 
The lipid-CPT samples from freeze-drying or film preparation were brought to room 
temperature for about 15 minutes before rehydration. Subsequently 3 ml 0.025 M PBS with 
pH 6.0 was added to the lipid film and 1ml to the freeze-dried cake for hydration. The lipid-
CPT mixture was vortexed and shaken to ensure that all the lipids were dispersed in the 
buffer. The dispersion was then ready for further size reduction. 
 
2.4 Size reduction of liposomes 
After rehydration with buffer, it is assumed that the liposomes are present in multilamellar 
vesicles (MLVs). To reduce the size and lamellarity of liposomes high energy must be 
delivered to the liposome dispersion. There are several methods to reduce MLVs to SUVs, 









2.4.1 Bath sonication 
The hand shaken MLVs film were sonicated in 3 ml portions in 15 minutes intervals using a 
bath sonicator G112SPIT Special Ultrasonic Cleaner (Laboratory supplies Co.,Inc.,USA). The 
sonicator and the samples were allowed to cool for ten minutes between each interval. 
 
2.4.2 Direct probe sonication 
Sonication of liposomes made by the film hydration method 
The hand shaken MLVs film were placed in an ice bath and sonicated in 3 ml quantity with an 
ultrasonic vibra cell (Sonics and Materials, USA) using a 19 mm needle probe tip and an 
output of 40 % max. The different formulations were sonicated in intervals of two minutes 
until the desired size was reached. The probe and the dispersion were allowed to cool for ten 
minutes between each interval. Upon sonication, the sample were placed in the fridge at 4 °C 
for equilibration overnight before further experiments were performed. 
 
Sonication of liposomes from the freeze-drying hydration methods 
The freeze dried samples were sonicated in a similar procedure as the hydrated liposome 
films. The sonication intervals were the same, but due to the smaller 1 ml quantity, the 
samples were sonicated using a Sonics high intensity ultrasonic processor (Sonics and 
Materials, USA) with a 13 mm needle tip that can accommodate a volume of 1 ml. Upon 
sonication, the sample were placed in the fridge at 4 °C for equilibration overnight before 







2.4.3 Size determination by photon correlation spectroscopy (PCS) 
The particle size and distribution of the sonicated liposomes can be measured by photon 
correlation spectroscopy (PCS), which is based on dynamic light scattering. The principle is 
based upon Brownian motion of particles in the solution. Small particles diffuse much faster 
than large particles, affecting the rate of fluctuation of scattered light intensity. The PCS 
instrument focuses laser light to the sample, and registers any movement from particles in 
solution (Torchilin and Weissig, 2003) (User manual, Nicomp Model 380,1997). 
PCS measurements of particle size and distribution were performed on Nicomp TM model 
380 particle sizing system (USA). In order to avoid impurities in the sample, sample 
preparation was measured in clean environment using particle free equipments. The cuvettes 
(borosilicate glass) were bath sonicated (Branson® 1510) for 10 minutes in freshly filtered 
PBS pH 6.0. Then all the samples and equipment needed were carried out in a laminar air-
flow LAF bench prior to use. The test tubes were rinsed with PBS pH 6.0 filtered through a 
0.22 µm pore size syringe filter. For measurement, the sample was diluted in filtered PBS pH 
6.0 until a stable intensity of approximately 250-350 kHz was achieved (User manual, 
Nicomp Model 380, 1997).  
The following instrument parameters described below were used in accordance with 
(Ingebrigtsen, 2001) with some exceptions. The buffer used was 0.025 M PBS pH 6.0.  
 
• Nicomp distribution 
• Automatic choice of channel width 
• Number weighting 
• Temperature 23 ˚C 
• Liquid index of refraction: 1.333 
• Laser wavelength : 632.8 nm (Helium-Neon) 
• Liquid viscosity: 0.933 CP 
• Scattering angle: 90˚ (Fixed angle) 
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• Number of cycles: 3 
• Run time: 15 minutes 
 
2.5 Ultracentrifugation 
To separate excess CPT, crystals, titanium particles from the sonication probe and lipid 
aggregates from the liposomes, an ultracentrifuge was employed. CPT crystals and lipid 
aggregates have a higher density than the small probe sonication liposomes, and will settle in 
the pellet upon ultracentrifugation. The SUVs with associated CPT will be present in the 
supernatant. 500 µl PBS pH 6.0 was added to 2 ml of the liposomal dispersion in a 3-ml thick 
wall polycarbonate centrifuge tube to raise the volume enough to fill the centrifuge tube. The 
samples were vortexed for 30 seconds prior to centrifugation, and were then centrifuged using 
Beckman Optima L8-M centrifugation with SW60Ti rotor (Beckman Inc.,USA). The 
centrifugation speed was 100 000 g, the temperature 10 ˚C and duration was optimized to 
separate free CPT crystals and lipid aggregates from the liposomes (Saetern et al., 2004b). 
Totally 900 µl of the supernatant was then carefully withdrawn for further determination of 
amount of CPT and PC as well as further studies on retention ability. 
 
2.5.1 Fluorescence microscopy 
In order to ensure that the ultracentrifugation method was optimized so that there were no 
CPT crystals in the supernatant, the supernatant was examined using a fluorescence 
microscopy Leica CTR 6000 microsystem (Germany). CPT is itself fluorescent so no external 
labelling of the CPT crystals was needed. The supernatant was examined by applying a drop 
on a glass clean slide and put a cover glass on top. It was important to avoid air bobbles 
between the glass slide and the cover glass. The preparation was examined under the 
microscope using a 20 x objective and filter set A, yielding an excitation wavelength of 360 
nm with a bandwidth of 40nm and recording fluorescence at 470 nm (bandwidth 40 nm) with 
a dichromatic mirror at 400 nm. Images were recorded using Leica Application Suite version 
2.5.0 R1 (Germany).  
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2.6 CPT liposomes retention ability 
The different formulations ability to retain CPT after incorporation was investigated using the 
spin column method. The principle behind the column filtration is that liposomes do not 
penetrate into the pores of the beads packed in the column, but instead percolates through the 
interbead spaces. Proteins as well as free drug are smaller in size and will be retarded in the 
pores of the bead pack. It is therefore assumed that CPT associated liposomes will be 
separated from the serum proteins as well as free CPT and will be collected in the early 
fractions. The formulations’ retention ability both in buffer and serum could be obtained using 
this method.  
 
2.6.1 Spin column method 
The different formulations’ ability to retain the drug in buffer and serum was investigated by 
using the spin column method (Torchilin and Weissig, 2003). 2.5 ml gel SeparatorGel 
Agarose Beads ACL 4% (Sooner Scientific) was packed in spin columns (Bio-Rad) using 
centrifuge Biofuge Startos (Heraeus Instruments, UK). The centrifuge was stopped manually 
when speed of 400 rpm was reached.  
300 µl of supernatant was diluted 1:2 v/v with PBS pH 6.0 and incubated at room 
temperature. Another 300 µl of supernatant was diluted 1:2 v/v with serum and incubated at 
37 ˚C. Separations of the incubated samples were measured at 0 hours, 5 hours and 24 hours 
and the samples were separated into 4 different fractions. Separations were done by adding 
100 µl of CPT-liposome dilution to a column. First fraction was collected in an eppendorf-
tube by centrifugation of the column until a speed of 400 rpm was reached. Further, the 
second fraction was collected in a new eppendorf-tube by adding 100 µl PBS buffer pH 6.0 to 
the column and performing the same centrifuge procedure as describe above. The same 
process was repeated twice more using 100 µl PBS buffer pH 6.0 and the fractions collected 
in eppendorf- tubes. Above, every fraction was diluted 1:2 v/v with Triton 10 % for further 





2.7 Quantification of Camptothecin 
High performance liquid chromatography (HPLC) was used to quantify Camptothecin (CPT) 
in the liposomes. The method described by Warner and Burke (Warner and Burke, 1997) was 
used with some modifications. Samples were diluted 1:2 with 10 % triton solution to dissolve 
the liposomes and release the incorporated CPT from the liposomes prior the analysis. Each 
sample was analyzed in triplicates. 
Quantification was achieved using CPT standards both in lactone and carboxylate form within 
a concentration range from 0.5 µM to 5.0 µM. The standard curve exhibited good linearity 
with a correlation coefficient of 0.997 ± 0.001 (n = 3). 
Following HPLC-method was used:  
• Mobile phase:  
   A: 25% Acetonitrile in 1% (v/v) triethylamine acetate buffer pH 5.5 and adjusted to       
        pH 5.99 
   B: 35% Acetonitrile in 1% (v/v) triethylamine acetate buffer pH 5.5 and adjusted 
        pH 6.32 
   C: 95% Acetonitrile in 5% distilled water (v/v) 
• 474 scanning fluorescence detector 
• Detection Wavelengths: Excitation λ=360 nm, Emission λ=440 
• Column: Waters Symmetri C18-column (3.9x150 mm) 
• Injection volume: 10 µl 
• Flow rate: 1.0 ml/min 
• Run time: 15 min 
• Sample temperature: 25˚C 




2.8 Quantification of phosphatidylcholine 
Quantification of amount of phosphatidylcholines in liposomes was performed by using an 
enzyme assay, Wako LabAssay Phospholipid B test kit (USA). The assays are based on 
phospholipids (lecithin, sphingomyelin, lysolecithin) being hydrolyzed by phospholipase D 
enzyme yielding choline as the product. Choline is further oxidized by choline oxidase in a 
reaction which forms hydrogen peroxide. The latter takes part in a peroxidase-catalyzed 
coupling which produces a blue pigment. The amount of phospholipids in the sample can be 
determined by measuring the absorbance of the blue colour (Grohganz et al., 2003) (User 
manual, Wako Chemicals).  
 
 
Figure 2.1: Enzymatic quantification of phosphatidylcholine (PC) (User manual,WAKO 




The assay was performed using a microtiter plate. Each microtiterplate was filled with 25 µl 
of the sample and 275 µl of colouring reagent. The plate was subsequently incubated at 37 ˚C 
for 15 minutes prior the absorbance measurements at 600 nm performed with a microtiterplate 
reader. All samples and standards were prepared and measured in triplicate (Grohganz et al., 
2003). 
This method was used after ultracentrifugation of liposomes to quantify phosphatidylcholine 
(PC) in the supernatant and pellet as well as to quantify the amount of PC in the fractions 
from the retention study.  
PC recovery in the supernatant after ultracentrifugation was calculated as follows: 
• PC recovery = (Mean amount of PC in supernatant / mean amount of PC in total  
dispersion) 
The results from the incorporation study were adjusted based on the recovery to make the 
comparison easier. 
PC content in fractions collected from the columns were used to determine the percentage of 
liposomes contained in each fraction compared to the original sample (either diluted in buffer 
or serum) used for the retention analysis. For each sample, the fraction with the highest PC 
content was used for CPT determination. If the PC content in this fraction was 40% of the 
original sample, it was assumed that 40% of the liposomes were eluted in this fraction. The 
results from the retention study were adjusted according to the percentage of liposomes in the 
fraction to relate to the amount of lipids in the original sample.  
 
2.9 Determination of zeta Potential of liposomes 
Surface properties of liposome formulations can vary depending on the composition of the 
lipid. There are cationic, anionic and neutral lipids, which can be used for preparation of 
liposomes. Zeta potential can be used to identify any correlation between the liposome 
incorporation and retention of CPT and surface charge properties of the liposomes (Brgles et 
al., 2008). The zeta potential is charge at the slip plane of the particle surface, and although it 
is not a direct measurement of the surface charge, it is a good estimation. Zeta potential is one 
of the important factors affecting liposomes stability, incorporation efficiency and interactions 
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with biological system in vivo(Gjelstrup Kristensen, 2000) (Labhasetwar et al., 1994). The 
zeta potential of liposomes was measured using a zetasizer Nano ZS (Malvern, UK). 
The samples were thus analyzed using the zetasizer. Prior to analysis the samples were diluted 
1 in 10 with PBS pH 6.0. The zetasizer capillary cell was also rinsed with 96 % ethanol and 
distilled water using a 1-ml syringe prior to analyses as recommended by the manufacturer. 
The diluted samples were then analyzed for ten cycles with a voltage of 4 mV. 
 
2.10 Fluorescence anisotropy 
To evaluate distribution of CPT in the liposomes, we used intrinsic fluorescence of CPT by 
fluorescence polarization measurements to examine mobility of CPT in the liposomal bilayer. 
Polarization measurements were performed on a fluorescence spectrophotometer (Perklin 
Elmer, UK) and a number of liposomal compositions were investigated. The samples were 
analyzed in a rectangular quartz fluorometer cell, and the excitation and emission wavelengths 














3. RESULTS AND DISCUSSIONS 
3.1 Method development 
In this study the method of incorporation capacity screening presented by Saeterns group 
(Saetern et al., 2004b) was used. However, due to different type of equipment and a desire to 
improve the feasibility of the method some changes were done as described below. 
3.1.1 Sonication procedure  
It is well known that the sonication process may influence the size and size distribution of 
liposomes (Woodbury et al., 2006). The goal was to obtain a sufficient size reduction and 
monodispersed liposomal size. Since small liposomes is preferred for i.v. application, the 
liposomal size was set to be <200 nm in diameter (Saetern, 2004). In the study by Saeterns 
group (Saetern et al., 2004b) they used probe sonication with a (Labsonic U,B.Braun Biotech 
International, Leverkusen, Germany) at 50 W, but this equipment was not available for us so 
we had to find another way to prepare SUVs. In order to determine the optimal sonication 
process for our purpose, size determination by PCS was performed upon sonication. Due to 
the toxicity of CPT, we wanted to keep the CPT containing liposomes in closed containers for 
not to expose the environment. We therefore chose to employ the bath sonicator to obtain 
SUVs. The result of bath sonicated liposomes is displayed in Table 3.1.  
 
Table 3.1: Bath sonicated EPC liposomes with duration of 5 x 15 minutes 
Liposomal composition Mean particle size 
(nm ± SD) 
Polydispersity 
Index (P.I.)*  
EPC  704.3 nm ± 41.5 0.755 
*P.I. represents the polydispersity index used as indication of size distribution of vesicles. 
Lower values of P.I. indicate more homogeneous liposomal sample. 
As described in Table 3.1 the measured size of the liposomes was found to be very large even 
after sonication for five intervals of fifteen minutes. The P.I is as well quit high indicating that 
the efficiency of size reduction is low and the samples are containing highly polydispersed 
population of liposome.  
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The liposome size, standard deviation of the mean particle size and the large P.I suggests that 
bath sonicator was not appropriate for size reduction of our liposomes, in addition the process 
was quit time consuming. It was therefore decided to employ a more powerful sonicator to 
reduce the size in a more rapid and reproducible manner.  
 
3.1.1.1 Probe sonication  
Since bath sonication in a closed container showed not to be appropriate we had to choose 
probe sonication in an open container and place the sonicator in a closed box in an appropriate 
room (cytostatic laboratory) instead. The size reduction of the liposomes was performed using 
an Ultrasonics Vibra Cell (USA) with a needle probe of 19 mm diameter. In order to 
determine an optimal sonication process for size reduction of the liposomes, it was necessary 
to present number of trials and evaluate the impact of number of intervals and time duration 
on the liposomes.  
Due to the high temperature during sonication, there is a risk of lipid degradation. It is 
therefore necessary to keep the sonication time short, keep the system cooled and include a 
break between the sonication cycles. Optimal sonication conditions were evaluated in regard 
to vesicle size and size distribution by using EPC and EPC/Chol (90%:10%). The reason why 
we chose a formulation with cholesterol in addition to pure EPC was that it is expected that 
the inclusion of Chol in the liposomal bilayer makes it more rigid and more resistance to size 
reduction (New, 1990).  
The sonicated lipsomes was tested by PCS upon sonication and results are shown in Table 
3.2. The liposomes obtained after 2x2min of sonication showed a satisfied size for the EPC 
formulation. In the case of EPC/Chol formulation the results show larger vesicle size in 
comparison with the EPC formulation. The sonication time was therefore increased for this 
formulation, and the results show an obvious size reduction for our purpose after three 







Table 3.2: Probe sonicated liposomes 
Duration  Liposomal composition Mean particle 




2 x 2 min EPC  42.9 nm ± 2  0.328 
2 x 2 min EPC-Chol (90%/10%) 228.9 nm ± 5  0.712 
3 x 2 min EPC-Chol (90%/10%) 32.5 nm ± 2  0.392 
 
 
3.1.2 Optimization of ultracentrifugation for separation of free CPT from liposomes 
Separation of CPT crystals from liposomes by ultracentrifugation was used to be able to see 
how much drug is associated with the liposomes. CPT crystals and lipid aggregates have 
higher density than SUV liposomes, and will settle in the pellet upon ultracentrifugation. In 
order to ensure that the ultracentrifugation earlier described (Saetern et al., 2004b) was 
optimized for our liposomes, and that there were no CPT crystals in the supernatant, the 
supernatant obtained after 20 min of centrifugation at 100 000 g was examined using a 
fluorescence microscopy Leica CTR 6000 microsystem, as described in 2.7. Averages of 10 
to 20 pictures were taken of each sample and several different formulations were examined. 
Figures 3.1 and 3.2 are representative examples. 
Crystals of CPT could be visually distinguee from dissolved CPT because they appear as an 
intense spot while CPT in liposomes results in a less intense fluorescing background. The 
microscopy pictures (Figure 3.1) clearly show CPT-crystals in the supernatant upon 


























Figure 3.1: Fluorescence pictures from the examination under fluorescence microscope,   
Leica CTR 6000 microsystem, of the supernatant from the formulation number 1 after 





In order to determine the optimal conditions for ultracentrifugation and to avoid CPT-crystals 
in the supernatant, it was necessary to increase the duration to 25 minutes. Further, samples of 
the supernatant were again examined using the fluorescence microscope and the results are 










Figure 3.2: Fluorescence pictures from the examination under fluorescence microscope, 
Leica CTR 6000 microsystem, of the supernatant from the formulation number 1 after 
increasing the ultracentrifugation duration to 25 minutes. Observations were conducted using 
a 20 X objective 
 
Our microscopy analysis demonstrated that ultracentrifugation at 100 000 g for 25 minutes 
gave appropriate separation of CPT crystals from the liposomes, since no CPT crystals were 
visible in the supernatant after these ultracentrifugation conditions (see Figure 3.2).The latter 
centrifugation condition gave thus sufficient separation as revealed by the fluorescence 







3.1.3 Comparison of film and freeze-drying method 
As part of the development of a method to detect incorporation and retention of CPT in 
different liposome formulations, we compared CPT incorporation using two different methods 
for removing organic solvents from the lipid:CPT mix. We wanted to employ the film 
methods for our research, while the freeze-drying method had previously been employed for 
similar research in this lab. The purpose of the comparison of film and freeze-drying method 
was to determine if there are any significant differences in the incorporation capacity of CPT 
in the liposomes when using these two methods. The reason for this was that the freeze-drying 
method caused a lot of problems (M. Skar, personal communication) and we wanted to do it 
in a more appropriate way. The freeze drying method reported by Saetern and co-workers 
(Saetern et al., 2004b) is anyway a more suitable method when DMSO is used as the solvent 
for CPT. The method removes organic solvent by sublimation, and in order for this procedure 
to work properly the lipid mixture needs to be in the solid state at – 40 ˚C . We employed 
organic solvents Chloroform:Methanol (4:1 volume ratio) in the CPT stock solution as 
recommended by the manufacturer. DMSO was not used as we expected better mixing of the 
lipids and the CPT in organic phase before drying, using the Chloroform:Methanol mixture. It 
is more difficult to remove chloroform to obtain a dry cake using freeze-drying. For this 
reason it was decided in advance to use the film method if there were no major differences 
between the incorporation capacities of CPT between these two methods. 
However, due to drying problems with the Freeze dryer (beta 2-16 equipped with an LMC-2 
controller, Martin Christ Gefriertrocknungsanlagen GmbH, Osterode am Herz, Germany) we 
only achieved one parallel of formulation number 1 using this method. The result of the 
comparison is displayed in Figure 3.3. It appears that there are no significant differences in 
CPT-incorporation between these two methods. The variations are within the standard 






Figure 3.3: Camptothecin-incorporation capacity of EPC (formulation 1) by film (n=3) and 
freeze-drying method (n=1).  
 
The freeze-drying problems is mainly related to our choice of solvents for preparation of CPT 
stock solution which was Chloroform:Methanol (4:1 volume ratio). Chloroform has a melting 
point of - 63 ˚C and by using the procedure as described in 2.3.2 it appeared some difficulties 
to sublimate the solvent to vapour. The melting point of chloroform might indicate that the 
solvent did not pass through the solid state and become sublimated, but rather evaporated 
when raising the temperature from – 40 ˚C to 45 ˚C and lowering the pressure from                       
800 to 0.08 mAtm within 65 hours. Moreover, CPT-incorporated liposomes approach 
performed earlier by Saetern and co-workers (Saetern et al., 2004b) gave reproducible data in 
their studies, probably due to their choice of solvent. Saetern et al (Saetern et al., 2004b) 
employed DMSO for preparation of CPT stock solution, and gained dry lipid cakes. DMSO 
has a melting point of 18.4 ˚C, and will be in the solid state and further become sublimated 
when raising the temperature from – 45 ˚C to 45 ˚C, while reducing the pressure.  
However, it looks like these two methods is comparable as was expected and the film method 
was chosen as the method for further liposome preparation due to less troublesome 
preparations.  


























3.2 Characterization of how lipid composition influences CPT incorporation and retention 
Earlier studies in our research group has revealed that the lipid composition of the liposomes 
have an effect on the CPT incorporation capacity (Saetern et al., 2004b) (unpublished results). 
In this study we wanted to investigate these effects in more detail by changing the lipid 
composition based on the previously studies. We also wanted to look at the different 
formulations retention ability since it is not enough that the drug is incorporated it also needs 
to stay with the liposomes in circulation. 
 
3.2.1 CPT liposome incorporation study 
Five liposome formulations with lipids of varying carbon chain length, saturation and charge 
as shown in Table 2.4 were prepared with a total concentration of 1 mg CPT/130 µmoles 
lipid, and the content of CPT in the liposomes was quantified after ultracentrifugation. As the 
molecular weight of the lipids varied significantly, especially later when PEG lipids were 
used, we based the formulations on 1 mg CPT/130 µmol lipid which is equivalent to 1 mg 
CPT/100 mg of EPC. Results from incorporation in the tested formulations are presented in 
Figure 3.4.  
Figure 3.4: Camptothecin-incorporation capacity of the different liposome formulations        
(n = 3) 
 




























The most promising formulations in this study were formulation 4 and formulation 5, which 
exhibited a significantly higher CPT-incorporation capacity compared to the other liposome 
formulations displayed in Figure 3.4. Both these formulations contain DOTAP and this is 
likely the main reason for the higher incorporation capacity. As we can see in Figure 3.4 the 
incorporation efficacy increases with a raising DOTAP content from 15 mol % to 20 mol %, 
although the two are not significantly different. Increased incorporation capacity observed in 
our results, corresponds with earlier studies and observations (Saetern et al., 2004b). 
Correlation between presence of DOTAP in liposomes and increased incorporation capacity 
previously studied by Saetern and co-workers (Saetern et al., 2004b), indicates that CPT have 
a higher affinity for cationic lipids such as DOTAP as compared with other non-charged 
lipids. Since CPT exists in a pH dependent equilibrium between its lactone isomer and 
negatively charged carboxylate isomer, the latter may bind to the cationic liposomes through 
electrostatic interactions and lead to increased incorporation of CPT within the cationic 
liposomes.  
The non-charged formulations, 1 and 3 do show lower incorporation capacities compared to 
the negative charged formulation. In comparison with literature, Cortesi and co-workers 
(Cortesi et al., 1997) reported that addition of Chol seems to raise the incorporation from 50 
% to 57 %. In  the contrary, other studies done by Saetern and co-workers (Saetern et al., 
2004b) and Daouds group (Daoud et al., 1995) observed that addition of Chol presented in the 
membrane reduced CPT-incorporation capacity. However, a direct comparison of these 
results can not be made due to differences in experimental approach, as well as the higher 
amount of Chol in the liposomes from Saeterns group compared to those in our research.  
A slight tendency toward increased incorporation was observed in formulation 2, when the 
negative charged lipid DOPG was presented in the PC membrane. This formulation contained 
10 % DOPG and 90 % EPC, and as we can see in Figure 3.4, addition of DOPG raised the 
incorporation capacity as compared with formulation 1 containing 100 % EPC. This result are 
corresponding with the study done by Sugarmans group (Sugarman et al., 1996), which 
suggested that use of DOPG solubilised the drug-lipid particles to a higher degree. Also 
Saeterns group reported increased incorporation capacity when negative charged DPPG was 
present in the liposome formulation (Saetern et al., 2004b). Any effect by using the longer and 
more unsaturated oleyl fatty acid chain instead of palmitoyl was however not observed 
compared to what has been reported earlier (Saetern et al., 2004b).  
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3.2.2 CPT liposomes retention ability 
A liposome formulations’ ability to retain the incorporated drug is a prerequisite for 
successful delivery of drug to the target. The retention abilities for the different formulations 
were therefore investigated.  
The retention ability of CPT of the five formulations shown in Table 2.4 was investigated 
over time, with withdrawal of samples after 0, 5, and 24 hours of incubation both in buffer 
and serum as described in section 2.6.1. 
 
 
Figure 3.5: The different liposome formulations ability to retain CPT, associated with the 
liposomes over time in buffer at room temperature (n = 3)  
 
The results of retention incubated in buffer at room temperature are displayed in Figure 3.5, 
and show different retention ability depending on the liposome formulations. There are no 
significant differences between the formulation containing EPC (formulation 1, Table 2.4) 
and EPC-DOPG (formulation 2, Table 2.4), which exhibit a slightly lower and decreasing 
retention ability during the incubation at room temperature. However, the most prominent 






































EPC-DOTAP 15% (formulation 4, Table 2.4), which leads to less drug leakage from the 
liposomes as compared to the other formulations. In general, none of the formulations (Figure 
3.5) appears to retain CPT within the liposomes to high degree. However, the results exhibit 
high standard deviations. We assume that the high standard deviations are due to the packing 
of the gel (SeparatorGel Agarose Beads ACL 4%) in the columns. The columns were packed 
using a centrifuge without set time function, and had to be stopped manually when it reached 
the desired rpm. We assume that this resulted in different packing of the gel material in the 
columns, which may have led to incomplete or varying elution of the liposomes of the 
columns.  
Liposomes in serum are most likely disposed to interact with blood components. One effect of 
this is drug loss to aggregates such as lipoproteins (Silvander et al., 1998). 
The retention abilities of the formulations in serum were also investigated by the column 
method as described above. The results are presented in Figure 3.6, and summarize the 
different formulations’ CPT retention ability over time when incubated in serum at 37 ˚C.  
 
Figure 3.6: The different liposome formulations ability to retain CPT, associated with the 





































As we can see in Figure 3.5 and 3.6 there are no significant differences between retention 
ability in buffer and serum for the three first formulations right after the dilution i.e. t = 0. 
Moreover, the liposomes retention ability seems to decrease when these three formulations 
were incubated in serum compared to in buffer. The most promising results are the DOTAP 
containing formulations incubated in serum, which exhibit a trend toward higher liposomal 
retention compared to the other liposome formulations. Although formulation 4 and 5 shows 
better retention ability, only 25 % of the drug is associated with the liposomes, which is far 
from being optimal.  
In the case of serum containing samples, variations in the column production may have led to 
incomplete separation of liposomes and serum proteins. This might be the major reason of the 
high standard deviations. Due to the high standard deviation as described, more studies have 
to be done before any conclusion can be made. Another separate method to analyse retention, 
based on dialysis, is being developed so that the above results can be confirmed. 
 
3.2.3 CPT liposomes incorporation ability and the influence of the zeta potential 
Zeta potential of the different liposome formulations were measured to identify if there are 
any correlations between incorporation and retention ability and surface charge properties of 
the liposomes. The result is given in Figure 3.7 and shows a plot of measured zeta potential of 
the different liposomes. 






























Liposomes which consist of EPC and EPC-Chol show a zeta potential of around 0 mV. A 
decrease of zeta potential is seen for the anionic lipid DOPG included in the liposome 
formulation 2. Further, the zeta potential starts to increase when the cationic DOTAP is 
employed in the liposomes, which is all according to what was expected. 
A correlation between absolute zeta potential and incorporation efficacy, are presented in 
Figure 3.8 and a trend toward increased CPT retention ability is seen when the absolute 
surface charge of the liposomes becomes higher. However it is hard to draw any clear 
conclusions since increasing concentration of DOTAP also has shown increased CPT 
incorporation. 
 
Figure 3.8: Correlation between liposomal Zeta potential (mV) and incorporation efficacy. 




































3.3 Preliminary studies on PEGylated liposomes 
As mentioned earlier, PEGylation of parenteraly administered liposomes are important to 
avoid opsonisation and rapid clearance from the blood circulation in vivo. The aim of the PEG 
inclusion to these liposomes was therefore to investigate whether the PEG had an effect on the 
CPT-incorporation capacity as well as retention ability, and to avoid rapid in vivo clearance in 
future studies. 
 
3.3.1 PEGylated CPT liposomes incorporation study 
As the EPC-DOTAP formulations showed increased CPT- incorporation in comparison to the 
other formulations displayed in Figure 3.4, these formulations were chosen for further PEG 
studies. Moreover, since the incorporation capacity of formulation 4 and 5 was quite similar, 
formulation 4 containing EPC-DOTAP 15 % was chosen for further PEG studies. 
Furthermore, DOTAP is more expensive than the other naturally occurring lipids and has a 
higher toxicity in vivo. The option was therefore to start with the lowest DOTAP content, 
which was 15 %, and see if same incorporation results could be obtained with inclusion of 
different ratios of PEG.  
 Incorporation capacity of PEGylated liposomes (formulation 6-8 in Table 2.4) were prepared 
with a total concentration of 1 mg CPT/130 µmoles lipid, and the content of CPT in the 
liposomes was quantified after ultracentrifugation as described in section 2.5. We utilized 
DSPE-PEG lipids where the PEG had a molecular weight of 2000 Da. The results of the 











Figure 3.9: Comparison of Camptothecin-incorporation between the PEGylated and non-
PEGylated liposomes. Formulation 5 (n = 3), formulation 6 (n = 4), formulation 7 (n = 1), 
formulation 8 (n = 2) 
  
The use of PEG resulted in an important observation. Reduced CPT incorporation capacity 
was observed when different ratios of PEG were included in the DOTAP/EPC formulation 
compared to the EPC/DOTAP formulation whiteout PEG (see Figure 3.9). As we observed, 
there are no significant differences between formulation 6 which contains 1 % PEG and 
formulation 8 containing 10 % PEG. Formulation 7 shows a relatively higher incorporation 
capacity as compared with formulation 6 and 8. Due to technical problems that appeared 
during the preparation, unfortunately we obtained only one parallel of formulation 7. This 
makes the comparison with the other formulations more difficult. Overall, PEG inclusion into 
the cationic liposomes reduced the incorporation capacity. The reason for the reduced 
incorporation when PEG is included is not completely understood, but we hypothesize that 
the DSPE-PEG chains might affect the fluidity of the liposomes, decreasing the incorporation 
of the drug into the membrane. PEG has a neutralization effect on the liposomes, and as seen 
in Figure 3.11 PEG also reduces the zeta potential as expected, thereby possible diminish the 
favourable effect of the cationic lipids. The neutralization effect of PEG was linearly 































3.3.2 PEGylated CPT liposomes retention ability 
The CPT retention ability of the PEGylated formulations shown in Table 2.4 was investigated 
over time, with withdrawal of samples after 0, 5, and 24 hours of incubation both in buffer 
and serum as described in section 2.8 and results are presented in Figure 3.10. 
 
Figure 3.10: The different PEGylated liposomal formulations ability to retain CPT, associated 
with the liposomes over time in buffer and serum (n = 1 for PEG 1 % and 5 %, and                   
n = 2 for PEG 10 %) 
 
Depending on PEG ratios employed in the liposomes, different leakage profiles were 
observed. The results show that inclusion of different ratios of PEG to the liposomes 
influences the formulations’ ability to retain the drug. The presence of 1 % and 10 % PEG 
show better retention and slower drug leakage from the liposomes compared to 5 % PEG 
formulation as displayed in Figure 3.10. Although we do not have results from several 
parallels of 1 % and 5 % PEG formulations, the results indicate that inclusion of PEG 
influence the formulations’ ability to retain the drug and a tendency toward improved 
retention ability is observed especially when 1 % PEG is included. Leakage of drugs from the 
bilayer is thought to be related to fluidity and packing order of the membrane. It seems like 











































is assumed to alter the surface characteristics and reduce the leakage from the liposomes 
(Brandl, 2001)  
 
3.3.3 PEGylated liposomes CPT incorporation and the influence of zeta potential 
Zeta potential of the different PEGylated formulation was measured to see how PEG is 
influencing the zeta potential as well as how much one have to include to get a zeta potential 
around zero. The results are displayed in Figure 3.11.  
 
 
Figure 3.11: Zeta potential of PEGylated liposomal formulations (n = 3) 
 
As expected, inclusion of neutral PEG into EPC/DOTAP liposomes resulted in decreasing 
zeta potential shifting towards zero. The zeta potential decreased with an increasing PEG 
inclusion leading to a neutralization of the liposomal surface charge.  
The decreased zeta potential resulted in decreased CPT incorporation within the liposomes, 
thereby removing the favourable effect of the cationic lipids. Although the zeta potential 
































ability further. The research on PEGylated liposomes so far indicates that the PEG inclusion 
could have a favourable effect on CPT retention.  
 
3.4 Fluorescence  anisotropy 
The fluidity of the liposomal bilayer membrane was investigated by fluorescence 
depolarization anisotropy in an attempt to find a relation between drug incorporation and 
retention ability with the membrane fluidity. The incorporated CPT was employed as a 
fluorescent probe to investigate changes in mobility and packing of the hydrocarbon acyl 
chains in the bilayer. CPT’s rotational freedom in the bilayer dictates the degree of 
polarization. An increased anisotropy value indicates less rotational freedom for the drug 
trapped in the liposome, which conserves the polarization of the incoming light. We used the 
intrinsic fluorescence of CPT to measure anisotropy, so that a lower anisotropy value would 
indicate that the CPT molecules had a more rotational freedom in the membrane, and were 
therefore more loosely trapped. A number of liposomal compositions were investigated, and 
Figure 3.12 summarizes the findings.  




























As shown in Figure 3.12 we saw little differences between the non-PEGylated formulations, 
most likely due to that these measurements are not specific enough toward retention to expose 
the small differences we discovered in the column experiments. We expected to see increased 
anisotropy with increased retention and decreased incorporation in liposomal formulations, 
hypothesizing that these drugs were more tightly trapped in the liposomal membrane. 
Contrary to what we expected, the PEG containing formulations as a group exhibited lower 
anisotropy while demonstrating an increased retention of the drug on the column experiments. 
In light of these results we conclude that anisotropy alone is an incomplete measure of the 
liposomes’ ability to retain CPT over time. The reason for this can be manifold; I) The 
temperature dependent anisotropy measurements are done over a short time period just after 
ultracentrifugation, thereby not exposing the differences between the formulations after 
extended incubation with buffer. II) Leakage of CPT during the temperature dependent 
experiment will result in some background scattering of free CPT in solution, and it is unclear 
if this background scatter is linearly proportional to a reduction in anisotropy value. III) 
Different levels of CPT incorporation into the liposomes can result in different anisotropy 
values. It can be more optimal to measure anisotropy at different time point in the incubation 
period similar to the retention studies. The anisotropy measurements must be further 
optimized with another marker to yield meaningful data (see also section 4: Future 
perspectives) 
 
3.5 Fusing of liposomes and size measurements using PCS 
Charged liposomes are shown to be unstable in the presence of serum components, as 
indicated by rapid fusion, and leading to rapid clearance from the blood circulation (Mori et 
al., 1998). During the retention studies, we noticed that the sample solutions containing serum 
changed colour during the 24 hours of incubation to become whiter, more milk like. We 
hypothesize that fusion of liposomes is the reason of this. In order to check whether the 
hypothesis is correct or not, we analyzed some of the formulations on PCS. The results from 






Table 3.3: PCS results of some liposome formulations right after sonication (0 Hr) and after 
24 Hr incubation in buffer and serum 
  0 Hr 24 Hr buffer 24 Hr serum 
Duration  Liposomal composition Mean particle size 
(nm ± SD) 
  
2 x 2 min EPC 42.9 nm ± 2 40 nm ± 2 259.6 nm ± 
11 
2 x 2 min EPC-DOPG (90%:10%) 37.3 nm ± 1 50.2 ± 0.1 105.2 nm ± 2 
3 x 2 min EPC-Chol (90%/10%) 32.5 nm ± 2 36.7 nm ± 2 280.2 nm ± 
23 
2 x 2 min EPC-DOTAP (80%: 20%) 30 nm ± 3 70 nm ± 2 120 nm ± 5 
2 x 2 min EPC-DOTAP (85%:15%) 28.9 nm ± 2 80.8 nm ±2 107.8 nm ± 3 
2 x 2 min EPC-DOTAP-PEG 
(85%:15%:1%) 
75.1 nm ± 4 78.6 nm ± 4 77.3 nm ± 5 
2 x 2 min EPC-DOTAP-PEG 
(85%:15%:5%) 
68.9 nm ± 1 71.3 nm ± 3 72.6 nm ± 4 
2 x 2 min EPC-DOTAP-PEG 
(85%:15%:10%) 
48.5 nm ± 0.5 49.8 nm ± 1 49 nm ± 1 
The results represent the mean of tree cycles (3 x 15 minutes) 
*Hr = hours  
 
Results displayed in Table 3.2 indicate that the size of liposome formulations without PEG 
attachment increases in presence of serum during the incubation time. This indicates that the 
milk like appearance is related to the liposome fusion which represents an irreversible 
process. As described above, it is known that charged liposomes exhibit instability and 
interacts with different serum components. This might be one of the reasons of the charged 
liposomes rapid fusion. It is also known that temperature conditions may influence liposome 
fusion, and since the serum containing samples were incubated respectively at 37 ˚C, this may 
have influenced the fusion rate of the neutral liposomes. 
In order to use fusogenic liposomes in drug delivery systems in vivo, they have to be designed 
in such way to become stable in the circulation for an extend period of time, and to avoid 
opsonisation before they reach the desired target site.  
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The PCS results of PEG containing liposomes do not show any size alteration during the 
incubation period, and we conclude that PEG inclusion in the liposomes stabilizes their size 
under the incubation conditions by decreasing the fusion of liposomes. We also see that 1 % 
PEG is enough to prevent fusion, we wanted to minimize the effect of reduced incorporation 






















In the first part of this thesis establishment of appropriate methods for incorporation and 
retention studies were performed. A comparison of lipid film and freeze-drying method was 
done and no major differences were seen between the different methods according to 
incorporation capacity of CPT. The film method was thus chosen as the method for further 
liposome preparation. Further, bath sonication and direct probe sonication were compared in 
terms of preparation of SUVs. The latter method gave satisfied size reduction for our purpose 
and was used during the study. For separation of liposomes from CPT-crystals a 
centrifugation approach was used. Centrifugation at 100 000 g for 20 minutes was found not 
sufficient for removal of CPT crystals from the supernatant. Upon changing the duration to 25 
minutes, all crystals were settled in the pellet and no CPT-crystals were visible under the 
fluorescence microscope. 25 minutes centrifugation was concluded to be the appropriate 
centrifugation condition for our study. 
Second, CPT-liposomes with different lipid compositions were prepared and evaluated for 
incorporation capacity and retention ability. The incorporation capacity of CPT within the 
liposomes was found to be highest for positively charged DOTAP-containing liposomes as 
compared with other formulations containing zwitterionic or negatively charged 
phospholipids. The DOTAP-containing liposomes exhibited as well a trend toward higher 
retention ability in serum compared to the other formulations tested.  
Third, in the preliminary PEGylation studies the PEG containing liposomes showed lower 
incorporation capacity compared to the liposomes without PEG, while better retention and 
slower leakage from the liposomes was seen when 1 % and 10 % PEG was included in the 
liposomes. In addition, PEG inclusion in the liposomes resulted in less fusion of liposomes 
during incubation in both buffer and serum. From the results it can be seen that 1 % PEG is 
enough to prevent fusion during the incubation, but further investigation are still needed to 
find optimal PEG ratios that can avoid opsonisation in further in vivo studies. 
In summary we have made progress towards establishing a method for producing and testing 
of CPT-liposomes as well as indentifying a formulation that effectively can incorporate CPT 
and retain the drug in circulation. However, we have yet to arrive at the ideal formulation, 
and, as we are still evaluating elements that affect all areas of incorporation and retention, 




5. Future Perspectives 
There is a need for further investigation and optimization of the protocol for the retention 
study to yield reproducible data. One method to measure the retention ability of the liposomes 
that is currently being tested is by employing dialysis. Dialysis is a process of separating 
small molecules from macromolecules such as proteins in a solution using a semi-permeable 
membrane. Dialysis operates by diffusion, which leads to movement of molecules from areas 
of higher to lower concentrations. By employing a dialysis membrane with the right 
molecular cut-off, the small CPT molecules will freely diffuse across the semi-permeable 
membrane into a second chamber of liquid until equilibrium is reached (Aulton, 2007). Both 
buffer and serum or protein solution could be used as acceptor medium to look at the 
influence of presence of proteins, and samples can be taken from the dialysis chamber at set 
time-points. Using this method no measurements of PC-recovery is needed for the retention 
studies, and liposome samples can be analyzed directly by the HPLC. By varying the different 
dialysis conditions, the liposomes’ retention ability in different environments can be 
investigated. 
The fluorescence anisotropy measurement must also be further investigated and optimized to 
yield more information. One way that may optimize this measurement is to employ a 
hydrophobic probe like1,6-Diphenyl-1,3,5-hexatriene (DPH) in the bilayer to investigate the 
bilayer fluidity and thus be able to predict CPT’s rotational freedom in the bilayer. The 
advantage with DPH before CPT is that it is easy to dissolve in the lipid bilayer which will 
ensure the same concentration of a probe in all the different formulations (Silvander et al., 
2000). 
It is clear that further studies needs to be done to reach the goal of a formulation appropriate 
for further in vivo studies. It would thus be of great interest to continue developing selected 
formulations as well as introduce new elements into the formulations to achieve a desirable 
incorporation and retention of CPT. Studies done by Watanabe group (Watanabe et al., 2008) 
and Maitani group (Maitani et al., 2008) has shown that inclusion of various artificial lipids in 
liposomes, especially benzoic acid derivatives can increase the incorporation capacity and 
retention of CPT in liposomes both in vitro and in vivo.. This might be due to an interaction 
between a phenyl group on the lipids and CPT by a π-π interaction. Another interesting 
approach that may improve the incorporation and retention ability of CPT-liposomes is by 
including polymerizable diacetylene into the liposomal bilayer. Polydiacetylene molecules are 
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generally non-toxic molecules, and form polymerized vesicles under UV irradiation. Such 
polymerizable vesicles are found to be more stable in comparison with unpolymerized 
vesicles, and therefore more suitable prolonged release drug delivery. In vitro study done by 
Guo group (Guo et al., 2010) show that conjugated backbone of the molecules by the 
photopolymerization acts as a barrier for drug release. Higher polymerization degree is shown 
to lead to a more sustained release of the drug from liposomes. It would be of great interest to 
develop these formulations, and investigate CPTs’ incorporation and retention ability within 
these liposomes.  
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